A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
Crossref DOI link: https://doi.org/10.1186/s12913-016-1607-z
Published Online: 2016-08-05
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Patel, Charmi A.
Bailey, Robert A.
Vijapurkar, Ujjwala
Meininger, Gary
Blonde, Lawrence
Funding for this research was provided by:
Janssen Scientific Affairs, LLC.
